# Bicalutamide With or Without Metformin for Biochemical Recurrence in Overweight or Obese Prostate Cancer Patients

> **NCT02614859** · PHASE2 · COMPLETED · sponsor: **Fox Chase Cancer Center** · enrollment: 29 (actual)

## Conditions studied

- Cancer of Prostate

## Interventions

- **DRUG:** Observation and Bicalutamide
- **DRUG:** Metformin and Bicalutamide

## Key facts

- **NCT ID:** NCT02614859
- **Lead sponsor:** Fox Chase Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-01
- **Primary completion:** 2020-01-24
- **Final completion:** 2020-01-24
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2022-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02614859

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02614859, "Bicalutamide With or Without Metformin for Biochemical Recurrence in Overweight or Obese Prostate Cancer Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02614859. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*